Frederic Chereau | Chief Executive Officer
LogicBio Therapeutics

Frederic Chereau, Chief Executive Officer, LogicBio Therapeutics

Frederic Chereau currently serves as President and Chief Executive Officer of LogicBio Therapeutics. From 2014 to 2015, Mr. Chereau was President and Chief Operating Officer of aTyr Pharma (LIFE). During his tenure, the company advanced multiple programs to clinical stage and successfully completed private financing and an IPO. Prior to that, Mr. Chereau was Senior Vice President and Angioedema Franchise Lead at Shire (SHPG), where he defined and oversaw the execution of the global strategy for the franchise, positioning it as the leader on its market. From 2008 to 2012, as President and Chief Executive Officer of Pervasis Therapeutics, he led the company through key strategies leading up to the acquisition of the company by Shire. Before Pervasis, Mr. Chereau worked at Genzyme from 1999 to 2008, where he held roles with increasing responsibility, initially within Genzyme France and Genzyme Europe, and achieved the position of Vice President and General Manager of the Cardiovascular Business Unit at Genzyme Corporation. Prior to Genzyme, he started his career at Hemotech, where he held sales and marketing roles. Mr. Chereau serves as a member of the Comite Strategique d’Orientation at La Rochelle Business School. He holds a B.S. in Physics from Paris University, received his master’s degree in management from La Rochelle Business School in France, and received an MBA from INSEAD, Fontainebleau, France and Singapore.


Conference Day 2: Friday 17th May 2019 @ 09:00

Keynote panel discussion: Exploring advances in gene editing technology, therapeutics and research

  • Best strategies for implementing new methods across the field of clinical research, now and for the future
  • Optimisation of the delivery of gene editing technology
  • How to minimise off-target effects and mutations for the safe and effective delivery of gene editing technology
  • Discussion of ethical and regulatory challenges, current legislation, how to navigate ethical concerns in light of the growing scale of genome editing. Most recently the CRISPR babies that were born in 2018
last published: 14/May/19 13:35 GMT

back to speakers

The World Advanced Therapies and Regenerative Medicine Congress and Exhibition is an international conference and exhibition featuring the latest in advanced therapies, bioengineering and surrounding technology. To attend the conference which features global leaders in the biopharma and regenerative medicine industries, there is a registration fee. The exhibition is free to visit.

Register your pass here.